title: New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma.
authors.affiliation: Westmead Institute for Cancer Research, University of Sydney at Westmead; Millennium Institute; Westmead Hospital, Sydney, Australia.
authors.forename: Matteo S
authors.initials: MS
authors.lastname: Carlino
authors.affiliation: Westmead Hospital, Sydney, Australia.
authors.forename: Vu
authors.initials: V
authors.lastname: Kwan
authors.affiliation: Queensland Centre for Medical Genomics; Institute of Molecular Bioscience, University of Queensland, St Lucia, Brisbane, Australia.
authors.forename: David K
authors.initials: DK
authors.lastname: Miller
authors.affiliation: Westmead Hospital, Sydney, Australia.
authors.forename: Catherine A B
authors.initials: CA
authors.lastname: Saunders
authors.affiliation: Canberra Hospital and Australian National University Medical School, Canberra, Australia.
authors.forename: Desmond
authors.initials: D
authors.lastname: Yip
authors.affiliation: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia.
authors.forename: Adnan M
authors.initials: AM
authors.lastname: Nagrial
authors.affiliation: Westmead Hospital, Sydney, Australia.
authors.forename: Jeanne
authors.initials: J
authors.lastname: Tomlinson
authors.affiliation: Queensland Centre for Medical Genomics; Institute of Molecular Bioscience, University of Queensland, St Lucia, Brisbane, Australia.
authors.forename: Sean M
authors.initials: SM
authors.lastname: Grimmond
authors.affiliation: Melanoma Institute Australia; Royal Prince Alfred Hospital, Sydney, Australia.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Scolyer
authors.affiliation: Westmead Institute for Cancer Research, University of Sydney at Westmead; Millennium Institute; Westmead Hospital; Melanoma Institute Australia, Sydney, Australia.
authors.forename: Richard F
authors.initials: RF
authors.lastname: Kefford
authors.affiliation: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney; South Western Sydney Clinical School, University of New South Wales, Liverpool, Australia; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow; Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom.
authors.forename: Andrew V
authors.initials: AV
authors.lastname: Biankin
authors.affiliation: Melanoma Institute Australia; The University of Sydney and Westmead Institute for Cancer Research, Sydney, Australia georgina.long@sydney.edu.au.
authors.forename: Georgina V
authors.initials: GV
authors.lastname: Long
mesh_terms: D000230:Adenocarcinoma / Q000139:chemically induced* / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001706:Biopsy; D004252:DNA Mutational Analysis; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects; D007150:Immunohistochemistry; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000556:secondary*; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009154:Mutation; D010091:Oximes / Q000008:administration & dosage / Q000009:adverse effects; D010190:Pancreatic Neoplasms / Q000139:chemically induced* / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D016283:Proto-Oncogene Proteins p21(ras); D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology*; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D018631:ras Proteins / Q000235:genetics*
chemical_list: D007093:Imidazoles; C117307:KRAS protein, human; D010091:Oximes; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; D011728:Pyridones; D011744:Pyrimidinones; C560077:trametinib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020930:MAP Kinase Kinase Kinases; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; C561627:dabrafenib